Obstructive sleep apnea (OSA) is a recognized risk factor for cardiovascular disorders. Thus, an association between endothelin-1 (EDN1) and OSA can be assumed. We investigated a cohort of 364 consecutive patients (age 57 ± 10 years) with mild to severe OSA for the EDN1 variant Lys198Asn (G/T) and endothelin plasma levels and compared them with 57 controls. The Lys198Asn genotype was significantly associated with the apnea/hypopnea index (AHI) with a median of 30/h of sleep for GG, 27/h for GT and 59/h for TT genotype (p < 0.05). Further stratification of patients into 2 groups by body mass index (BMI) revealed a strong association between AHI and Lys198Asn polymorphism in 191 obese patients (p = 0.005), whereas in 173 nonobese patients, we observed no association. A substantial effect by BMI on OSA severity was seen with multiple linear regression (p < 0.001). However, this effect was modified by the Lys198Asn polymorphism and by gender: the AHI increase per unit of BMI was more pronounced in males than in females, and about 1.3 times greater in homozygous carriers of the mutant allele than in other carrier groups. EDN1 plasma levels of untreated OSA patients and of patients treated with nasal continuous positive airway pressure were not elevated compared with controls. Our results indicate that the Lys198Asn polymorphism is associated with the severity of OSA in obese subjects. The EDN1 plasma level cannot be used as a marker for OSA or its severity.

Keywords:
Sleep apnea, Endothelin-1, Lys198Asn
1.
Grote L, Ploch T, Heitmann J, Knaack L, Penzel T, Peter JH: Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999;160:1875–1882.
2.
Newman AB, Nieto FJ, Guidry U, Lind BK, Redline S, Pickering TG, Quan SF, Sleep Heart Health Study Research Group: Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001;154:50–59.
3.
Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378–1384.
4.
Palmer LJ, Redline S: Genomic approaches to understanding obstructive sleep apnea. Respir Physiol Neurobiol 2003;135:187–205.
5.
Redline S, Tishler PV: The genetics of sleep apnea. Sleep Med Rev 2000;4:583–602.
6.
Tishler PV, Larkin EK, Schluchter MD, Redline S: Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. J Am Med Assoc 2003;289:2230–2237.
7.
Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, Kamada N, et al: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703–710.
8.
Taheri S, Mignot E: The genetics of sleep disorders. Lancet Neurol 2002;1:242–250.
9.
Levin ER: Endothelins. N Engl J Med 1995;333:356–363.
10.
Asai T, Ohkubo T, Katsuya T, Higaki J, Fu Y, Fukuda M, Hozawa A, Matsubara M, Kitaoka H, Tsuji I, Araki T, Satoh H, Hisamichi S, Imai Y, Ogihara T: Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects. Hypertension 2001;38:1321–1324.
11.
Brown MJ, Sharma P, Stevens PA: Association between diastolic blood pressure and variants of the endothelin-1 and endothelin-2 genes. J Cardiovasc Pharmacol 2000;35:S41–S43.
12.
Jin JJ, Nakura J, Wu Z, Yamamoto M, Abe E, Tabara Y, Yamamoto Y, Igase M, Kohara K, Miki T: Association of endothelin-1 gene variant with hypertension. Hypertension 2003;41:163–167.
13.
Kozak M, Holla LI, Krivan L, Vasku A, Sepsi M, Borivoj S, Vacha J: Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia. Med Sci Monit 2002;8:BR164–BR167.
14.
Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMurray JJ, Dargie HJ, Arveiler D, Ruidavets JB, Luc G, Evans A, Cambien F: The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999;33:1169–1174.
15.
Treiber FA, Barbeau P, Harshfield G, Kang HS, Pollock DM, Pollock JS, Snieder H: Endothelin-1 gene Lys198Asn polymorphism and blood pressure reactivity. Hypertension 2003;42:494–499.
16.
Vasku A, Spinarova L, Goldbergova M, Muzik J, Spinar J, Vitovec J, Toman J, Vacha J: The double heterozygote of two endothelin-1 gene polymorphisms (G8002A and -3A/-4A) is related to big endothelin levels in chronic heart failure. Exp Mol Pathol 2002;73:230–233.
17.
Barden AE, Herbison CE, Beilin LJ, Michael CA, Walters BN, Van Bockxmeer FM: Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens 2001;19:1775–1782.
18.
Grimpen F, Kanne P, Schulz E, Hagenah G, Hasenfuss G, Andreas S: Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J 2000;15:320–325.
19.
Lavie L: Obstructive sleep apnoea syndrome – an oxidative stress disorder. Sleep Med Rev 2003;7:35–51.
20.
Moller DS, Lind P, Strunge B, Pedersen EB: Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003;16:274–280.
21.
Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK: Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999;17:61–66.
22.
Saarelainen S, Seppala E, Laasonen K, Hasan J: Circulating endothelin-1 in obstructive sleep apnea. Endothelium 1997;5:115–118.
23.
Saarelainen S, Hasan J: Circulating endothelin-1 and obstructive sleep apnoea. Eur Respir J 2000;16:794–795.
24.
Gjorup PH, Sadauskiene L, Wessels J, Nyvad O, Strunge B, Pedersen EB: Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens 2007;20:40–52.
25.
Giannessi D, Del Ry S, Vitale RL: The role of endothelins and their receptors in heart failure. Pharmacol Res 2001;43:111–126.
26.
Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573–1579.
27.
Parrinello G, Scaglione R, Pinto A, Corrao S, Cecala M, Di Silvestre G, Amato P, Licata A, Licata G: Central obesity and hypertension: the role of plasma endothelin. Am J Hypertens 1996;9:1186–1191.
28.
American Academy of Sleep Medicine Task Force Report: Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;22:667–689.
30.
Fietze I, Diefenbach K: Healthy sleepers are rare: problems and success rates in establishing a control group for sleep studies. Neuropsychopharmacology 2003;28:558–561.
31.
Suzuki N, Matsumoto H, Miyauchi T, Kitada C, Tsuda M, Goto K, Masaki T, Fujino M: Sandwich-enzyme immunoassays for endothelin family peptides. J Cardiovasc Pharmacol 1991;17(suppl 7):S420–S422.
32.
Diefenbach K, Nahad FA, Meisel C, Fietze I, Cascorbi I, Stangl K, Landt O, Kerb R, Brinkmann U, Roots I: Identification of 12 polymorphisms in the endothelin-1 gene using fluorescence-labelled oligonucleotides and PCR-RFLP methods. Clin Chem 2004;50:448–512.
33.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Rocella E, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
34.
Schiffrin EL: State-of-the-art lecture. Role of endothelin-1 in hypertension. Hypertension 1999;34:876–881.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.